Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.
AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.
UC Irvine Healthcare is the first medical center on the West Coast and the only one in California to perform robotic thyroidectomies, a procedure that removes the diseased gland without leaving a visible scar on the neck. Dr. Jason Kim, associate clinical professor of otolaryngology and a head and neck cancer specialist, has performed robotic-assisted surgery using the daVinci Surgical System on three patients with thyroid tumors.
The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.
Scientists are using the engineering technology behind the creation of high-performance aircraft components to design 3-D models for the replacement of delicate and complex facial bones lost to cancer surgery or trauma.
Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.
Past and present patients, families, friends, staff and physicians of ProCure Proton Therapy Center in Oklahoma City commemorated a year of achievements at a celebratory luncheon Thursday at the center in northwest Oklahoma City.
CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.
Disfigurement can be a challenging and distressing experience for many of the 1 million people in the UK who have a visible difference of any kind.
Data on the effects of coffee on cancer risk have been mixed. However, results of a recent study add to the brewing evidence that drinking coffee protects against cancer, this time against head and neck cancer.
Recently, oral cancer survivor Jeanna Richelson, organized the first Chattanooga Oral Cancer Awareness Walk, which raised donations for the Oral Cancer Foundation, and much needed awareness of a disease that too few Americans know about. According to the foundation's executive director Brian Hill, "I don't believe there has ever been an oral cancer walk that was this successful in its first year. This was an absolutely amazing effort by Jeanna and those who helped her make this possible."
Phylogeny, the in situ company, and Neoprobe, a diversified developer of innovative biomedical surgical oncology products, announce their collaboration to develop head and neck cancer detection technology.
IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing.
Head and neck cancer surgeons at UT Southwestern Medical Center performed the area's first transoral robotic surgery (TORS), a recently approved minimally invasive no-scar procedure to remove tumors in the throat.
Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.
Robotic surgery - is it truly an advance for modern medicine, or just a product of slick consumer advertising campaigns and targeted marketing to physicians?
For the second year, the Nashville Area Dental Hygienists' Society (NADHS) has organized a successful walk to promote oral cancer awareness for a disease that affects so many, yet so few know about. Hundreds of Nashville locals gathered for the "Boot Scootin' for Oral Cancer Screening II" event that recently took place at Nashville's Centennial Park to raise disease awareness, and funds for the Non-Profit Oral Cancer Foundation (OCF).
Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.